Stifel Reiterates BioMarin Pharmaceutical (BMRN) at Buy, Believes the Stock Can Outperform on Strong Voxogo Launch and Roctavian Approvals
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $96.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
